Viruses 2010, 2(2), 503-531; doi:10.3390/v2020503
Review

HIV Genetic Diversity and Drug Resistance

1email and 1,2,* email
Received: 18 November 2009; in revised form: 11 December 2009 / Accepted: 1 February 2010 / Published: 2 February 2010
(This article belongs to the Special Issue HIV Drug Resistance)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Most of the current knowledge on antiretroviral (ARV) drug development and resistance is based on the study of subtype B of HIV-1, which only accounts for 10% of the worldwide HIV infections. Cumulative evidence has emerged that different HIV types, groups and subtypes harbor distinct biological properties, including the response and susceptibility to ARV. Recent laboratory and clinical data highlighting such disparities are summarized in this review. Variations in drug susceptibility, in the emergence and selection of specific drug resistance mutations, in viral replicative capacity and in the dynamics of resistance acquisition under ARV selective pressure are discussed. Clinical responses to ARV therapy and associated confounding factors are also analyzed in the context of infections by distinct HIV genetic variants.
Keywords: HIV-1; drug resistance; genetic diversity; subtypes; clinical response
PDF Full-text Download PDF Full-Text [244 KB, uploaded 2 February 2010 11:45 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Santos, A.F.; Soares, M.A. HIV Genetic Diversity and Drug Resistance. Viruses 2010, 2, 503-531.

AMA Style

Santos AF, Soares MA. HIV Genetic Diversity and Drug Resistance. Viruses. 2010; 2(2):503-531.

Chicago/Turabian Style

Santos, André F.; Soares, Marcelo A. 2010. "HIV Genetic Diversity and Drug Resistance." Viruses 2, no. 2: 503-531.

Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert